Short, Nicholas J.

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax

Kim, K., Maiti, A., Loghavi, S., Pourebrahim, R., Kadia, T. M., Rausch, C. R., Furudate, K., Daver, N. G., Alvarado, Y., Ohanian, M., et al. (2021) · Cancer

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 161

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

Short, N. J., Kantarjian, H. M., Loghavi, S., Huang, X., Qiao, W., Borthakur, G., Kadia, T. M., Daver, N., Ohanian, M., Dinardo, C. D., et al. (2019) · The Lancet Haematology

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 120

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia

Bidikian, A., Kantarjian, H., Jabbour, E., Short, N. J., Patel, K., Ravandi, F., Sasaki, K., & Issa, G. C. (2022) · Blood Cancer Journal

Chronic Myeloid Leukemia TreatmentsAcute Myeloid Leukemia Research

Cited by 55

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL

Zhao, Y., Short, N. J., Kantarjian, H. M., Chang, T.-C., Ghate, P. S., Qu, C., Macaron, W., Jain, N., Thakral, B., Phillips, A. H., et al. (2023) · Blood

Acute Lymphoblastic Leukemia researchCAR-T cell therapy research

Cited by 41

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL

Zhao, Y., Short, N. J., Kantarjian, H. M., Chang, T.-C., Ghate, P. S., Qu, C., Macaron, W., Jain, N., Thakral, B., Phillips, A. H., et al. (2024) · Blood

Acute Lymphoblastic Leukemia researchCAR-T cell therapy research

Cited by 41

TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation

Lontos, K., Saliba, R. M., Kanagal-Shamanna, R., Özcan, G., Ramdial, J., Chen, G., Kadia, T., Short, N. J., Daver, N. G., Kantarjian, H., et al. (2025) · Blood Advances

Acute Myeloid Leukemia ResearchHematopoietic Stem Cell Transplantation

Cited by 35

Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor

Bidikian, A., Jabbour, E., Issa, G. C., Short, N. J., Sasaki, K., & Kantarjian, H. (2023) · American Journal of Hematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 32